Document is current

Article History

Received: 17 December 2023

Accepted: 29 January 2024

First Online: 15 February 2024

Declarations

:

: This project was approved by the Peter MacCallum Cancer Centre (PMCC) ethics review committee (QA/77039/PMCC). <i>Consent to Participate</i>: Not applicable.

: Not applicable.

: SS: Speakers Bureau—AstraZeneca, Varian Medical Systems, Roche Pharmaceuticals. NH: Research grant funding for kidney SABR from Varian Medical Systems, and research grant funding from Reflexion Medical for biological guided radiation therapy. A consultant with SeeTreat Medical. AAA: Consultant—Astellas, Janssen, Novartis, Aculeus Therapeutics, Speakers Bureau—Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb; Merck Serono, Bayer. Honoraria—Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix; Merck Serono; Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm, Merck Sharpe Dome, Aculeus Therapeutics, Daiichi Sankyo. Scientific Advisory Board—Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix; Merck Serono; Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome, Amgen, Noxopharm,Daiichi Sankyo, Arvinas. Travel + Accommodation—Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar, Pfizer; Bayer. Research Funding—Astellas (investigator), Merck Serono (investigator), Astra Zeneca (investigator), Bristol Myers Squibb (institutional), Astra Zeneca (institutional), Aptevo Therapeutics (institutional), Glaxo Smith Kline (institutional), Pfizer (institutional), MedImmune (institutional), Astellas (institutional), SYNthorx (institutional), Bionomics (institutional), Sanofi Aventis (institutional), Novartis (institutional), Ipsen (institutional), Exelixis (institutional), Merck Sharpe Dome (institutional), Janssen (institutional), Eli Lilly (institutional), Gilead Sciences (institutional), Merck Serono (institutional), Hinova (institutional), Steering Committee—Astellas, Exelixis, Pfizer.